Antiphospholipid Syndrome: primary or secondary to Systemic Lupus Erythematosus? Description of a clinical case of avitaminosis D in premenopausal woman with pseudo-Cushing syndrome
DOI:
https://doi.org/10.7175/cmi.v8i2.912Keywords:
Antiphospholipid syndrome, Venous thromboembolism, Thrombocytopenia, Oral anticoagulation, Vitamin D, Systemic Lupus Erythematosus, Obesity, Autoantibodies, AutoimmunityAbstract
Low vitamin D levels have been described in obese individuals and in some autoimmune diseases, such as Systemic Lupus Erythematosus (SLE) and primary antiphospholipid syndrome (pAPS). In particular, more than 50% of premenopausal women with pAPS have hypovitaminosis D. In this issue we report a case of an obese, premenopausal, and hypertensive woman with pseudo-Cushing syndrome, affected by deep venous thrombosis associated with pulmonary embolism after rib fracture who presented hypovitaminosis D. 7 years before, diagnosis of pAPS had been made after the detection of thrombocytopenia (present at a young age) and arterial ischemia of a lower limb. For seven years she was treated with acetylsalicylic acid without complications. We found positive anti-dsDNA antibodies, a triple antiphospholipid antibodies (aPL) positivity and levels of vitamin D < 4 µg/l. The case report arises some questions: is vitamin D deficiency due to obesity or APS? Is the positivity of anti-dsDNA indicative of progression to SLE? Is preventive therapy with hydroxychloroquine indicated? Does the high-risk aPL profile justify a high-intensity and life-long anticoagulation regimen?
References
Amital H, Szekanecz Z, Szucs G, et al. Serum concentrations of 25-OH vitamin D in patients with systemic lupus erythematosus (SLE) are inversely related to disease activity: is time to routinely supplement patients with SLE with vitamin D? Ann Rheum Dis 2010; 69: 1155-7; http://dx.doi.org/10.1136/ard.2009.120329
Mok CC, Birmingham DJ, Leung HW, et al. Vitamin D levels in Chinese patients with systemic lupus erythematosus: relationship with disease activity, vascular risk factors and atherosclerosis. Rheumatology 2012; 51: 644-52; http://dx.doi.org/10.1093/rheumatology/ker212
Ritterhouse LL, Crowe SR, Niewold TB, et al. Vitamin D deficiency is associated with an increased autoimmune response in healthy individuals and in patients with systemic lupus erythematosus. Ann Rheum Dis 2011; 70: 1569-74; http://dx.doi.org/10.1136/ard.2010.148494
Klack K, Carvalho JF. High frequency of vitamin D insufficiency in primary antiphospholipid syndrome. Joint Bone Spine 2010; 77: 489-90; http://dx.doi.org/10.1016/j.jbspin.2010.02.043
Piantoni S, Andreoli L, Allegri F, et al. Low levels of vitamin D are common in primary antiphospholipid syndrome with thrombotic disease. Reumatismo 2012; 64: 307-13; http://dx.doi.org/10.4081/reumatismo.2012.307
Paupitz JA, Freire de Carvalho J, Caparbo VF, et al. Primary antiphospholipid syndrome in premenopausal women: low vitamin D, hight fat mass and maintained bone mineral mass. Lupus 2010; 19: 1302-6; http://dx.doi.org/10.1177/0961203310372938
Andreoli L, Piantoni S, Dall’Ara F, et al. Vitamin D and antiphospholipid syndrome. Lupus 2012; 21: 736-40; http://dx.doi.org/10.1177/0961203312446386
Agmon-Levin N, Blank M, Zandman-Goddard G, et al. Vitamin D: an instrumental factor in the anti-phospholipid syndrome by inhibition of tissue factor expression. Ann Rheum Dis 2011; 70: 145-50; http://dx.doi.org/10.1136/ard.2010.134817
Adami S, Romagnoli E, Carnevale V, et al. Linee guida su prevenzione e trattamento dell’ipovitaminosi D con colecalciferolo Reumatismo 2011; 63: 129-47
Wortsman J, Matsuoka LY, Chen TC, et al. Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr 2000; 72: 690-3
Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002; 46; 1019-27; http://dx.doi.org/10.1002/art.10187
Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306; http://dx.doi.org/10.1111/j.1538-7836.2006.01753.x
Ramos-Casals M, Campoamor MT, Chamorro A, et al. Hypocomplementemia in systemic lupus erythematosus and primary antiphospholipid syndrome: prevalence and clinical significance in 667 patients. Lupus 2004; 13: 777-83; http://dx.doi.org/10.1191/0961203304lu1080oa
Gòmez-Puerta JA, Martìn H, Amigo MC, et al. Long-term follow-up in 128 patients with primary antiphospholipid syndrome: do they develop lupus? Medicine 2005; 84: 225-30; http://dx.doi.org/10.1097/01.md.0000172074.53583.ea
Jung H, Bobba R, Su J, et al. The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthritis Rheum 2010; 62: 863-8; http://dx.doi.org/10.1002/art.27289
Costedoat-Chalumeau N, Leroux G, Piette JC, et al. Why all systemic lupus erythematosus patients should be given hydroxychloroquine treatment? Joint Bone Spine 2010; 77: 4-5; http://dx.doi.org/10.1016/j.jbspin.2009.09.007
Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, et al. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010; 69: 20-8; http://dx.doi.org/10.1136/ard.2008.101766
Akhavan PS, Su J, Lou W, et al. The early protective effect of hydroxychloroquine on the risk of cumulative damage in patients with systemic lupus erythematosus. J Rheumatol 2013; 40: 831-41; http://dx.doi.org/10.3899/jrheum.120572
Broder A, Putterman C. Hydroxychloroquine use is associated with lower odds of persistently positive antiphospholipid antibodies and/or lupus anticoagulant in systemic lupus erythematosus. J Rheumatol 2013; 40: 30-3; http://dx.doi.org/10.3899/jrheum.120157
Rand JH, Wu XX, Quinn AS, et al. Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-β2-glycoprotein I complexes to phospholipid bilayers. Blood 2008; 112: 1687-95; http://dx.doi.org/10.1182/blood-2008-03-144204
Rand JH, Wu XX, Quinn AS, et al. Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarian drug. Blood 2010; 115: 2292-9; http://dx.doi.org/10.1182/blood-2009-04-213520
Ruiz-Irastorza G, Cuadraro MJ, Ruiz-Arruza I, et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus 2011; 20: 206-18; http://dx.doi.org/10.1177/0961203310395803
Pengo V, Denas G, Banzato A, et al. Secondary prevention in thrombotic antiphospholipid syndrome. Lupus 2012; 21: 734-5; http://dx.doi.org/10.1177/0961203312444773
Crowter MA, Ginsberg JS, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003; 349: 1133-8; http://dx.doi.org/10.1056/NEJMoa035241
Finazzi G, Marchioli R, Brancaccio V, et al. A randomized clinical trial of high-intensity vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost 2005; 3: 848-53; http://dx.doi.org/10.1111/j.1538-7836.2005.01340.x
Pengo V, Ruffatti A, Legnani C, et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost 2010; 8: 237-42; http://dx.doi.org/10.1111/j.1538-7836.2009.03674.x
Cikrikcioglu MA, Hursitoglu M, Erkal H, et al. Splenomegaly in primary antiphospholipid syndrome without accompanying portal hypertension or comorbidity. Pathophysiol Haemost Thromb 2010; 37: 104-9
Published
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution Non-Commercial 4.0 Licence that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. The Publication Agreement can be downloaded here, and should be signed by the Authors and sent to the Publisher when the article has been accepted for publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
- Authors are permitted to post their work online after publication (the article must link to publisher version, in html format)